Otsuka Pharmaceutical

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

Otsuka Pharmaceutical Co., Ltd.
Native name
大塚製薬株式会社
Ōtsuka Seiyaku Kabushiki-gaisha
TypePublic KK
TYO: 4578
TOPIX 100 Component
IndustryPharmaceutical
Founded1921 (Originally founded), 1964 (Current corporation)
FounderBusaburo Otsuka
Headquarters
Chiyoda, Tokyo
,
Japan
Number of locations
69
Area served
Worldwide
Key people
Tatsuo Higuchi (President)
Revenue¥ 531.2 billion (2017)
¥ 57.0 billion (2017)
OwnerNomura Trust and Banking investment trusts (11.43%)
and investment trusts managed by other banks
Number of employees
5,634 (2017)
ParentOtsuka Holdings Co. Ltd
Websiteotsuka.com

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company.[1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]

Otsuka Pharmaceutical Co. Ltd Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.[2]

In 1986, Otsuka Holdings Co. Ltd. acquired Ridge Vineyards.[3]

In 1990, Otsuka Holdings Co. Ltd. acquired Crystal Geyser Water Company.[4]

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.[5]

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[6] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.[7]

In September 2013, Otsuka Holdings it acquired Astex Pharmaceuticals for close to $900 million.[8]

In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.[9]

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[10]

In July 2017, the business acquired Daiya.[11]

In July 2018, Otsuka agreed to acquire Visterra for $430 million cash[12] and renal-focused ReCor Medical, Inc.[13]

In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.

Acquisition history
Otsuka Pharmaceutical Acquisitions
  • Otsuka Pharmaceutical Co., Ltd

Products
Products of Otsuka Pharmaceutical

References
  1. Fujita, Junko; Slodkowski, Antoni (December 16, 2010), Nathan Layne (ed.), Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 (Reuters news), Forexyard, archived from the original on March 4, 2012, retrieved January 15, 2012
  2. "Tokushima Vortis". 15 January 2020. Retrieved October 30, 2020.
  3. "Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk".
  4. Otsuka.com Library Archived 2019-06-16 at the Wayback Machine, Otsuka Pharmaceutical. Retrieved September 21, 2019.
  5. "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A." otsuka.co.jp. May 28, 2008. Retrieved October 30, 2020.
  6. Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead, BioSpace, January 13, 2012, archived from the original on March 3, 2016, retrieved January 15, 2012
  7. UCB and Otsuka to focus collaboration on CNS disorders, Zenopa, January 13, 2012, retrieved January 15, 2012
  8. Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters.
  9. Soble, Jonathan (2 December 2014). "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". The New York Times. Retrieved 23 April 2018.
  10. "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. 3 March 2017. Retrieved 23 April 2018.
  11. "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka". Food Dive.
  12. "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms". July 11, 2018.
  13. "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement". BioSpace.
  14. "Aripiprazole". AdisInsight. Retrieved 4 June 2017.
  15. Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.